Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 30;9(3):86.
doi: 10.3390/diagnostics9030086.

HIV Viral Load Estimation Using Hematocrit Corrected Dried Blood Spot Results on a BioMerieux NucliSENS® Platform

Affiliations

HIV Viral Load Estimation Using Hematocrit Corrected Dried Blood Spot Results on a BioMerieux NucliSENS® Platform

Charles Nyagupe et al. Diagnostics (Basel). .

Abstract

While reporting human immunodeficiency virus (HIV) viral load (VL) using dried blood spot (DBS) in the BioMerieux NucliSENS platform, application of the hematocrit correction factor has been suggested. In this cross-sectional study from the National Microbiology Reference Laboratory of Zimbabwe, we assessed whether hematocrit correction (individual and/or mean) in DBS results improved the correlation with plasma VL and prediction of VL non-suppression (≥1000 copies per ml in plasma). Of 517 specimens during August-December 2018, 65(12.6%) had non-suppressed plasma VL results. The hematocrit correction factor ranged from 1.3 to 2.0 with a mean of 1.6, standard deviation (SD: 1.5, 1.7). The intraclass correlation (ICC) for mean (0.859, 95% CI: 0.834, 0.880) and individual (0.809, 95% CI: 0.777, 0.837) hematocrit corrected DBS results were not significantly different. The uncorrected DBS results had a significantly lower ICC (0.640, 95% CI: 0.586, 0.688) when compared to corrected DBS results. There were no significant differences in validity, predictive values, and areas under the receiver operating characteristics curves for all three DBS results when predicting VL non-suppression. To conclude, hematocrit correction of DBS VL results improved agreement with the plasma results but did not improve prediction of VL non-suppression. The results were not significantly different for individual and mean corrected results.

Keywords: Antiretroviral therapy (ART) monitoring; dried blood spot; hematocrit; human immunodeficiency virus; viral load.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
ROC curve*for uncorrected, mean hematocrit corrected and individual hematocrit corrected DBS HIV-RNA results in predicting VL non-suppression (≥1000 copies per mL) as measured in plasma, Zimbabwe National Microbiology Reference Laboratory, August–December 2018 (n = 517). ROC: receiver operating characteristic, DBS: Dried blood Spot; VL: viral load. * Area under curve for uncorrected DBS—0.933; mean hematocrit corrected DBS—0.933; individual hematocrit corrected DBS—0.932. The ROC curve for uncorrected DBS (purple line) is not seen as it is hidden below and overlapped by the ROC curve for mean corrected DBS (red line), their area under the curve are the equal.

Similar articles

Cited by

References

    1. UNAIDS . 90-90-90 An Ambitious Treatment Target to Help End the AIDS Epidemic. UNAIDS; Geneva, Switzerland: 2014.
    1. World Health Organization (WHO) Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. WHO; Geneva, Switzerland: 2016. - PubMed
    1. World Health Organization (WHO) Technical and Operational Considerations for Implementing HIV Viral Load Testing: Interim Technical Update. WHO; Geneva, Switzerland: 2014.
    1. Roberts T., Cohn J., Bonner K., Hargreaves S. Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges. Clin. Infect. Dis. 2016;62:1043–1048. doi: 10.1093/cid/ciw001. - DOI - PMC - PubMed
    1. Johannessen A., Trøseid M., Calmy A. Dried blood spots can expand access to virological monitoring of HIV treatment in resource-limited settings. J. Antimicrob. Chemother. 2009;64:1126–1129. doi: 10.1093/jac/dkp353. - DOI - PubMed

LinkOut - more resources